Pemphigus pathogenesis: problems and prospects

Abstract

Provides the survey of most prospective trends of research of the pathogenesis of the true acantholytic pemphigus. Cites key results of studies of factors of genetic predisposition to the development of this bullous dermatosis. Highlights problems of studies of the role of antiself antibodies and self-antigens in pemphigus pathogenesis. Represents the apoptolyse theory, explaining mechanisms of the loss of link between keratinocytes. Discusses issues of the cellular regulation of autoimmune reactions at acantholytic pemphigus.

Full Text

Патогенез вульгарной пузырчатки: проблемы и перспективы
×

References

  1. Потекаев Н.С., Кочергин Н.Г., Теплюк Н.П. и др. Терапевтическая тактика при стероидрезистентной вульгарной пузырчатке. Росс. журн. кож. и вен. бол. 2003; 2: 11-15.
  2. Hertl M. Autoimmune diseases of the skin. Pathogenesis, diagnosis, management. 3rd ed. Springer Wien New York 2011; 593.
  3. Махнева Н.В., Молочков В.А., Белецкая Л.В. Циркулирующие аутоантитела и оценка их роли в развитии аутоиммунной пузырчатки паранеопластического генеза. Вестн. дерматол. венерол. 2009; 2: 47-53.
  4. Langan SM, Smeeth L, Hubbard R et al. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ. 2008 Jul 9;337:a180.
  5. Robinson, J. C., Lozada-Nur, F., and Frieden, I. (1997) Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 84, 349-355.
  6. Ahmed, A. R., and Moy, R. Death in pemphigus. J Am Acad Dermatol 1982; 7: 221-228.
  7. Rosenberg, F. R., Sanders, S., and Nelson, C. T. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 1976; 112: 962-970.
  8. Теплюк Н.П.. Потекаев Н.Н., Кузьмина Т.С. и др. Летальный исход при кортикостероидной терапии акантолитической пузырчатки в результате инфекционных осложнений. Клин. дерматол. венерол. 2005; 2:16-20.
  9. Wucherpfennig K.W., Yu B., Bhol K. et al. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: Charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA Immunology 1995 December; 92: 11935-11939.
  10. Lombardi ML, Mercuro O, Ruocco V et al. Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients. J Invest Dermatol 1999 Jul;113(1):107-10.
  11. Birol A, Anadolu RY, Tutkak H et al. HLA-class 1 and class 2 antigens in Turkish patients with pemphigus. Int J Dermatol 2002 Feb;41(2):79-83.
  12. Tunca M, Musabak U, Sagkan RI et al. Association of human leukocyte antigen class II alleles with pemphigus vulgaris in a Turkish population. J Dermatol 2010 Mar;37(3):246-50. Литература
  13. Yamamoto T, Ikeda K, Sasaoka S et al. Human leukocyte antigen genotypes and antibody profiles associated with familial pemphigus in Japanese. J Dermatol 2011 Jul;38(7):711-6.
  14. Abida O., Zitouni M.,Kallel-Sellami M. et al. Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles. BJD 2009; 161: 522-527
  15. Lee E, Lendas KA, Chow S. Disease relevant HLA class II alleles isolated by genotypic, haplotypic, and sequence analysis in North American Caucasians with pemphigus vulgaris. Hum Immunol 2005 Dec;66(12):1213-22.
  16. Глухенький Б.Т., Грандо С.А. Иммунозависимые дерматозы: экзема, атопический дерматит, истинная пузырчатка, пемфигоиды. Киев: «Здоровья» 1990.
  17. Loiseau P, Lecleach L, Prost C, Lepage V, Busson M, Bastuji-Garin S, Roujeau JC, Charron D.HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus. Tissue Antigens 1999 Oct;54(4):333-40.
  18. Yamamoto T, Ikeda K, Sasaoka S et al. Human leukocyte antigen genotypes and antibody profiles associated with familial pemphigus in Japanese. J Dermatol 2011 Jul;38(7):711-6.
  19. Capon F, Bharkhada J, Cochrane NE et al. Evidence of an association between desmoglein 3 haplotypes and pemphigus vulgaris. J Autoimmun 2005 Sep;25(2):121-5.
  20. Martel P, Gilbert D, Drouot L et al. A polymorphic variant of the gene coding desmoglein 1, the target autoantigen of pemphigus foliaceus, is associated with the disease. Genes Immun 2001 Feb;2(1):41-3.
  21. Ayed MB, Martel P, Zitouni M et al. Tunisian endemic pemphigus foliaceus is associated with desmoglein 1 gene polymorphism. Genes and Immunity 2002; 3: 378-379.
  22. Petzl-Erler ML, Malheiros D. Pemphigus foliaceus and desmoglein 1 gene polymorphism: is there any relationship? J Dermatol 2005 Mar;32(3):186-8.
  23. Eberhard Y, Burgos E, Gagliardi J et al. Cytokine polymorphisms in patients with pemphigus. Cytokine 2004 Dec 21;28(6):233-41.
  24. Torzecka J. D., Narbutt J., Sysa-Jedrzejowska A. et al. Tumour necrosis factor-a polymorphism as one of the complex inherited factors in pemphigus. Mediators of Inflammation 2003 October; 12 (5): 303-307.
  25. Pereira NF, Hansen JA, Lin MT Cytokine gene polymorphisms in endemic pemphigus foliaceus: a possible role for IL6 variants. Arch Dermatol 2004 Jun;140(6):723-7.
  26. Javor J, Chmurova N, Parnicka Z et al. TNF-alpha and IL-10 gene polymorphisms show a weak association with pemphigus vulgaris in the Slovak population. Genes Immun 2009 Sep;10(6):547-58.
  27. Sarig O., Bercovici S., Zoller L. et al. Population-Specific Association between a Polymorphic Variant in ST18, Encoding a Pro-Apoptotic Molecule, and Pemphigus Vulgaris. J Invest Dermatol 2012 Mar 22. doi: 10.1038/jid.2012.46. [Epub ahead of print].
  28. Anhalt GJ, Labib RS, Voorhees JJ и др. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982 May 20;306(20):1189-96.
  29. Amagai M, Klaus-Kovtun V, Stanley JR. Auto-antibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991 Nov 29;67(5):869-77.
  30. Udey MC, Stanley JR. Pemphigus--diseases of antidesmosomal autoimmunity. JAMA 1999 Aug 11;282(6):572-6.
  31. Amagai M, Nishikawa T, Nousari HC et al. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 1998 Aug 15;102(4):775-82.
  32. Ding X, Diaz LA, Fairley JA et al. The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. J Invest Dermatol 1999 May;112(5):739-43.
  33. Vu TN, Lee TX, Ndoye A et al. The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity. Development of antibodies against keratinocyte cholinergic receptors in patients with pemphigus vulgaris and pemphigus foliaceus. Arch Dermato. 1998 Aug;134(8):971-80.
  34. Матушевская Е.В., Лысенко А.А., Свирищевская Е.В. Клинические особенности и иммунные механизмы патогенеза истинной пузырчатки. Совр. пробл. дерматовенерол. иммунол. врачебн. косметол. 2006; 1: 18-26.
  35. Koch PJ, Mahoney MG, Ishikawa H et al. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 1997 Jun 2;137(5):1091-102.
  36. Лысенко А.А., Коцарева О.Д., Матушевская Е.В. и др. Роль эндотелиального барьера в патогенезе pemphigus vulgaris. Мед. иммунол. 2006; 8: 2-3: 154.
  37. Grando S.A. Pemphigus autoimmunity: Hypotheses and realities. Autoimmunity 2012 February; 45(1): 7-35.
  38. Kalantari-Dehaghi M, Molina DM, Farhadieh M, et al. New targets of Pemphigus vulgaris antibodies identified by protein array technology. Exp Dermatol 2011;20:154-156.
  39. Kalantari-Dehaghi M, Anhalt G, Camilleri M et al. Pemphigus vulgaris antibodies target PERP and several other keratinocyte membrane and mitochondrial proteins. J Invest Dermatol 2011;131(Suppl. 1):S11.
  40. Ihrie RA, Marques MR, Nguyen BT Et al Perp is a p63-regulated gene essential for epithelial integrity. Cell 2005; 120:843-856.
  41. Davies L, Gray D, Spiller D et al. P53 apoptosis mediator PERP: Localization, function and caspase activation in uveal melanoma. J Cell Mol Med 2009;13:1995-2007.
  42. Amagai M, Tsunoda K, Zillikens D et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999 Feb;40(2 Pt 1):167-70.
  43. Grando S.A., Bystryn J., Chernyavsky A.I. Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis. Exp Dermatol 2009; 18: 764-770.
  44. Brandsen R, Frusic-Zlotkin M, Lyubimov H et al. Circulating Pemphigus IgG in families of patients with Pemphigus: Comparison of indirect immunofluorescence, direct immunofluorescence, and immunoblotting. J Am Acad Dermatol 1997;36:44-52.
  45. Torzecka JD, Narbutt J, Sysa-Jedrzejowska A et al. Detection of Pemphigus autoantibodies by IIF and ELISA tests in patients with Pemphigus vulgaris and foliaceus and in healthy relatives. Med Sci Monit 2003;9:CR528-CR533.
  46. Torzecka JD, Wozniak K, Kowalewski C et al. Circulating Pemphigus autoantibodies in healthy relatives of Pemphigus patients: Coincidental phenomenon with a risk of disease development? Arch Dermatol Res 2007;299:239-243.
  47. Veldman C, Stauber A, Wassmuth R et al. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with Pemphigusvulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol 2003;170:635-642.
  48. Hertl M, Amagai M, Sundaram H et al. Recognition of desmoglein 3 by autoreactive T cells in Pemphigus vulgaris patients and normals. J Invest Dermatol 1998;110:62-66.
  49. Veldman CM, Gebhard KL, Uter W et al. T cell recognition of desmoglein 3 peptides in patients with Pemphigus vulgaris and healthy individuals. J Immunol 2004;172:3883-3892.
  50. Ahmed AR, Mohimen A, Yunis EJ et al. Linkage of Pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med 1993;177:419-424.
  51. Gebhard KL, Veldman CM,Wassmuth R et al. Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with Pemphigus foliaceus and healthy individuals. Exp Dermatol 2005;14: 586-592.
  52. Sugiyama H, Matsue H, Nagasaka A e al. CD4 ю CD25 high regulatory T cells are markedly decreased in blood of patients with Pemphigus vulgaris. Dermatology 2007;214:210-220.
  53. Arakawa M, Dainichi T, Yasumoto S et al. Th17 cells in Pemphigus vulgaris and Pemphigus foliaceus. J Dermatol Sci 2009;53:228-231.
  54. Hertl M, Amagai M, Sundaram H et al. Recognition of desmoglein 3 by autoreactive T cells in Pemphigus vulgaris patients and normals. J Invest Dermatol 1998;110:62-66.
  55. Grando SA, Glukhenky BT, Drannik GN et al. Autoreactive cytotoxic T lymphocytes, in Pemphigus and Pemphigoid. Autoimmunity 1989;3: 247-260.
  56. Hata T, Nishifuji K, Shimoda K et al. Transgenic rescue of desmoglein 3 null mice with desmoglein 1 to develop a syngeneic mouse model for pemphigus vulgaris. J Dermatol Sci 2011 Jul;63(1):33-9.
  57. Sandor F, Buc M. Toll-like receptors. III. Biological significance and impact for human medicine. Folia Biol (Praha) 2005;51(6):198-203.
  58. Tang X, Zhang X. Drug-induced pemphigus after six years of treatment with phenytoin and carbamazepine. Int J Dermatol 2012 Apr;51(4):485-6.
  59. Feng S, Zhou W, Zhang J et al. Analysis of 6 cases of drug-induced pemphigus. Eur J Dermatol. 2011 Sep-Oct;21(5):696-9.
  60. Bowman C, Delrieu O. Immunogenetics of drug-induced skin blistering disorders. Part II: synthesis. Pharmacogenomics 2009 May;10(5):779-816.
  61. Nagao K, Tanikawa A, Yamamoto N et al. Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamine in drug-induced pemphigus foliaceus. Clin Exp Dermatol 2005 Jan;30(1):43-5.
  62. Sebaratnam DF, Martin LK, Rubin AI, et al. Reversible relapse of pemphigus foliaceus triggered by topical imiquimod suggests that Tolllike receptor 7 inhibitors may be useful treatments for pemphigus. Clin Exp Dermatol 2011 Jan;36(1):91-3.
  63. Bauza A, Del Pozo LJ, Saus C et al. Pemphiguslike lesions induced by imiquimod. Clin Exp Dermatol 2009 Jul;34(5):e60-2.
  64. Lo Schiavo A, Sangiuliano S, Puca RV et al. Contact pemphigus: a side-effect of imiquimod therapy. Int J Dermatol 2008 Jul;47(7):765-7.
  65. Mashiah J, Brenner S. Possible mechanisms in the induction of pemphigus foliaceus by topical imiquimod treatment. Arch Dermatol 2005 Jul;141(7):908-9; author reply 909.
  66. Lin R, Ladd DJ Jr, Powell DJ et al. Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch Dermatol 2004 Jul;140(7):889-90.
  67. Campagne G, Roca M, Martinez A. Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect. Eur J Obstet Gynecol Reprod Biol 2003 Aug 15;109(2):224-7.
  68. Meyer-Bahlburg A., Rawlings D.J. B cell autonomous TLR signaling and autoimmunity. Autoimmunity Reviews 7 (2008) 313-316.

Copyright (c) 2012 MICHENKO A.V., ZNAMENSKAYA L.F., LVOV A.N., VOLKOV I.A., FRIGO N.V., VOLNUKHIN V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies